| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 8251- | LCA, | Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 8275- | LCA, | Licochalcone A inhibits glioma migration, invasion, and growth by triggering mitochondrial dysfunction and ROS-mediated oxidative damage |
| - | vitro+vivo, | GBM, | NA |
| 8235- | LCA, | Anticancer effects of licochalcones: A review of the mechanisms |
| - | Review, | Var, | NA |
| 8229- | LCA, | Licochalcone A: a review of its pharmacology activities and molecular mechanisms |
| - | Review, | Nor, | NA |
| 8232- | LCA, | Licochalcone A induces G2/M phase arrest and apoptosis via regulating p53 pathways in esophageal cancer: In-vitro and in-vivo study |
| - | vitro+vivo, | ESCC, | NA |
| 8338- | LDN, | Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway |
| - | vitro+vivo, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
| 8339- | LDN, | Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo |
| - | in-vivo, | Cerv, | HeLa |
| 8291- | LE, | Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling |
| - | vitro+vivo, | AML, | TF1 |
| 8288- | LE, | 18 β-glycyrrhetinic acid exhibits potent antitumor effects against colorectal cancer via inhibition of cell proliferation and migration |
| - | vitro+vivo, | CRC, | NA |
| 8143- | LF, | Lactoferrin mediates epithelial-mesenchymal transformation by regulating the PI3K/AKT/mTOR pathway to inhibit nasopharyngeal carcinoma metastasis |
| - | in-vitro, | NPC, | NA |
| 8298- | lign, | Inhibitory Effects of Enterolactone on Growth and Metastasis in Human Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8324- | LIN, | Linalool targets NR3C2 to inhibit NF-κB-mediated gastric cancer progression |
| - | vitro+vivo, | GC, | NA |
| 8325- | LIN, | Validating linalool as a potential drug for breast cancer treatment based on machine learning and molecular docking |
| - | in-vitro, | BC, | NA |
| 8375- | LT, | Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches |
| - | Review, | Var, | NA |
| 8384- | LT, | Current situation and research progress of luteolin in the treatment of gastrointestinal malignant tumors |
| - | Review, | GC, | NA |
| 8390- | LT, | Luteolin in Inflammatory Bowel Disease and Colorectal Cancer: A Disease Continuum Perspective |
| - | Review, | IBD, | NA | - | Review, | CRC, | NA |
| 8400- | LT, | Luteolin inhibits triple-negative breast cancer by inducing apoptosis and autophagy through SGK1-FOXO3a-BNIP3 signaling |
| - | in-vitro, | BC, | NA |
| 8397- | LT, | Effects and Mechanisms of Luteolin, a Plant-Based Flavonoid, in the Prevention of Cancers via Modulation of Inflammation and Cell Signaling Molecules |
| - | Review, | Var, | NA |
| 8371- | LT, | Study on the regulatory mechanism of luteolin inhibiting WDR72 on the proliferation and metastasis of non small cell lung cancer |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Nor, | BEAS-2B |
| 4687- | LT, | QC, | Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 8348- | Lut, | Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1 |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA‑MB‑157 |
| 8343- | Lut, | Association of Lutein with Cancer: A Systematic Review of the Lutein Effects on Cellular Processes Involved in Cancer Progression |
| - | Review, | Var, | NA |
| 3262- | Lyco, | Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1 |
| - | in-vitro, | adrenal, | SK-HEP-1 |
| 3275- | Lyco, | Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer |
| - | Review, | Var, | NA |
| 4782- | Lyco, | New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene |
| - | Review, | Var, | NA |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 1126- | Lyco, | Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway |
| - | vitro+vivo, | Oral, | NA |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 8520- | MAG, | The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8518- | MAG, | Magnolol suppresses the proliferation and invasion of cholangiocarcinoma cells via inhibiting the NF-κB signaling pathway |
| - | in-vitro, | CCA, | NA |
| 8498- | MAG, | Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells |
| - | in-vitro, | Kidney, | 786-O | - | in-vitro, | RCC, | OS-RC-2 | - | in-vitro, | Nor, | HK-2 |
| 8499- | MAG, | Wnt/β-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells |
| - | vitro+vivo, | CRC, | SW480 | - | in-vitro, | CRC, | HCT116 |
| 8505- | MAG, | Role of magnolol in gastrointestinal cancers: Recent trends and future perspectives |
| - | Review, | GC, | NA |
| - | vitro+vivo, | CRC, | HT-29 | - | in-vitro, | Colon, | CT26 |
| 1196- | MAG, | 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression |
| - | in-vitro, | HCC, | NA |
| 4535- | MAG, | 5-FU, | Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways |
| - | in-vitro, | Cerv, | NA |
| 4531- | MAG, | Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4520- | MAG, | Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling |
| - | vitro+vivo, | PC, | PANC1 |
| 9283- | Maqui, | Hydroethanolic Extracts of the Aristotelia Chilensis (Maqui) Berry Reduces Cellular Viability and Invasiveness in the Endometrial Cancer Cell Line Ishikawa |
| - | in-vitro, | Endo, | NA |
| 8566- | Matr, | Matrine suppresses lung metastasis of human hepatocellular carcinoma by directly targeting matrix metalloproteinase-9 |
| - | vitro+vivo, | HCC, | MHCC-97H |
| 8569- | Matr, | Matrine inhibits the metastatic properties of human cervical cancer cells via downregulating the p38 signaling pathway |
| - | vitro+vivo, | Cerv, | NA |
| 8570- | Matr, | Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-κB signaling pathway |
| - | vitro+vivo, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 8576- | Matr, | Matrine reduces the proliferation and invasion of colorectal cancer cells via reducing the activity of p38 signaling pathway |
| - | vitro+vivo, | CRC, | NA |
| 8542- | Matr, | Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival Signaling |
| - | vitro+vivo, | Lung, | A549 |
| 8538- | Matr, | Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling |
| - | in-vitro, | BC, | MDA-MB-231 | - | ex-vivo, | BC, | MDA-MB-231 |
| 8537- | Matr, | Matrine restrains the development of colorectal cancer through regulating the AGRN/Wnt/β-catenin pathway |
| - | vitro+vivo, | CRC, | NA |
| 8530- | Matr, | Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial‑mesenchymal transition |
| - | in-vitro, | HCC, | NA |
| 8544- | Matr, | Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential |
| - | Review, | BC, | NA |
| 8555- | Matr, | Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:324 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid